

**RECEIVED
CENTRAL FAX CENTER****APR 14 2006**

S/N 10/826,094

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	MADHYASTHA	Examiner:	R. MONDESI
Serial No.:	10/826,094	Group Art Unit:	1653
Filed:	APRIL 16, 2004	Docket No.:	14233.16USU1
Confirmation No.:	9255	Customer No.:	23552
Title:	SYNERGISTIC MICROBIAL COMPOSITIONS AND METHOD FOR REDUCING BIOFILM FORMATION		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office on April 14, 2006.

By: _____
Name: John J. Jones**REQUEST FOR CORRECTED FILING RECEIPT**Commissioner for Patents
Filing Receipt Corrections
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a photocopy of the Filing Receipt from the United States Patent and Trademark Office in the above-identified application showing requested corrections. The filing receipt is erroneous in the following respects as reflected in the papers originally filed:

The Domestic Priority data is incorrect.

The correct priority information is:


This Application claims the benefit of 60/558,132 04/01/04.

Correction of the records of the United States Patent and Trademark Office and issuance of a corrected filing receipt are respectfully solicited.

23552

PATENT TRADEMARK OFFICE

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Brian R. Dorn, Ph.D.
Reg. No. 57,395

Date: April 14, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1430
 Alexandria, Virginia 22311-1430
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/826,094	04/16/2004	1614	585	14233.16USU1✓	8	35	1

CONFIRMATION NO. 9255

23552
 MERCHANT & GOULD PC
 P.O. BOX 2903
 MINNEAPOLIS, MN 55402-0903

BRD

UPDATED FILING RECEIPT

OC000000013884355

Date Mailed: 09/23/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Srinivasa Madhyastha, Winnipeg, CANADA;

Power of Attorney: The patent practitioners associated with Customer Number 23552.

Domestic Priority data as claimed by applicant

Foreign Applications

This application claims the benefit of 60/558,132,
 filed April 1, 2004

If Required, Foreign Filing License Granted: 06/26/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/826,094

Projected Publication Date: 10/20/2005

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

D

Synergistic antimicrobial compositions and methods for reducing biofilm formation**Preliminary Class**

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15****GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).